Arkin Bio Ventures identifies, invests in, and accompanies innovative early and mid-stage companies with game-changing breakthroughs in areas such as immunotherapy, cancer, metabolism, microbiome, central nervous system, autoimmune diseases, orphan diseases, and drug-delivery platforms.Arkin Bio Ventures' management team leads and supports its portfolio companies through the hurdles of drug development, towards the proof-of-concept stage and beyond, to significant value creation.

Arkin Bio Ventures is currently invested in companies in various stages of product development.

Arkin Bio Ventures is a joint venture between insurance and finance company Phoenix Group (49%) and Arkin Holdings (51%).

In 2016, the two companies announced a strategic collaboration agreement for investment in pharmaceutical and biotechnology companies, for a total of approximately $60 million (with an option to increase the investment in the future).

Arkin Bio Ventures is part of Arkin Holdings, a holding company aiming to empower pioneering developments in healthcare while focusing on pharmaceuticals, biotechnology, and medical devices.